Key result
The tandem giant magnetoresistance assay quantified NT-proBNP in human plasma within 15 minutes, demonstrating high correlation (r = 0.995) and agreement with the standard Roche Cobas e411 analyzer.
A novel dual-GMR microfluidic immunoassay provides rapid, accurate, and wide-range quantification of NT-proBNP from small plasma volumes, showing promise for point-of-care heart failure diagnostics.
We report a microfluidic sandwich immunoassay constructed around a dual-giant magnetoresistance (GMR) sensor array to quantify the heart failure biomarker NT-proBNP in human plasma at the clinically relevant concentration levels between 15 pg/mL and 40 ng/mL. The broad dynamic range was achieved by differential coating of two identical GMR sensors operated in tandem, and combining two standard curves. The detection limit was determined as 5 pg/mL. The assay, involving 53 plasma samples from patients with different cardiovascular diseases, was validated against the Roche Cobas e411 analyzer. The salient features of this system are its wide concentration range, low detection limit, small sample volume requirement (50 μL), and the need for a short measurement time of 15 min, making it a prospective candidate for practical use in point of care analysis.
No takes yet. Share an insight, caveat, or question.
Meng et al. (2021) studied Cardiovascular diseases (n=53). Tandem giant magnetoresistance (GMR) assay vs. Roche Cobas e411 analyzer was evaluated on Correlation and agreement for NT-proBNP quantification (r = 0.995). The tandem giant magnetoresistance assay quantified NT-proBNP in human plasma within 15 minutes, demonstrating high correlation (r = 0.995) and agreement with the standard Roche Cobas e411 analyzer.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: